GSK Plc GSK said it raised £885.6 million (around $1.08 billion) from selling some of its shares in Haleon Plc HLN, reducing its stake in the consumer-healthcare business to around 7.4%.
The British pharmaceutical giant placed around 270 million Haleon shares at 328 pence each, representing a 2.45% discount to Haleon's closing price on Thursday of 336.25 pence.
U.S. pharma giant Pfizer Inc PFE holds a 32% stake in Haleon and said it plans to cut ownership in a "slow and methodical" manner within months.
In May, GSK sold 240 million shares of Haleon in a move that has raised £804 million for the firm. The offloaded shares are equivalent to up to 2.5% of Haleon's issued share capital.
Following the settlement of the placing, GSK held 955 million ordinary shares in Haleon, representing approximately 10.3% of its issued share capital.
Citing a Bernstein analyst, Bloomberg noted, "Investors would likely prefer a bigger placement than this 2.9% by GSK," adding that there's still a large, nearly 40% overhang on Haleon stock.
"If a decent sized placement of about 10% was done (i.e., Pfizer starting to sell), then investors can properly judge the appetite for this stock and start seeing an end to this tunnel," the report added.
Price Action: GSK shares are up 0.58% at $36.37, and HLN shares are down 2.03% at $8.20 during the premarket session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.